346 related articles for article (PubMed ID: 17963805)
1. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.
Musa AM; Khalil EA; Mahgoub FA; Elgawi SH; Modabber F; Elkadaru AE; Aboud MH; Noazin S; Ghalib HW; El-Hassan AM;
Trans R Soc Trop Med Hyg; 2008 Jan; 102(1):58-63. PubMed ID: 17963805
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of intravenous sodium stibogluconate alone and in combinations with allopurinol, rifampicin, and an immunomodulator in the treatment of Indian post-kala-azar dermal leishmaniasis.
Ramesh V; Kumar J; Kumar D; Salotra P
Indian J Dermatol Venereol Leprol; 2010; 76(2):138-44. PubMed ID: 20228542
[TBL] [Abstract][Full Text] [Related]
3. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.
Melaku Y; Collin SM; Keus K; Gatluak F; Ritmeijer K; Davidson RN
Am J Trop Med Hyg; 2007 Jul; 77(1):89-94. PubMed ID: 17620635
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of an autoclaved Leishmania major vaccine.
Khalil EA; Elhassan AM; Zijlstra EE; Osman OF; Eljack IA; Ibrahim ME; Mukhtar MM; Ghalib HW; Modabbers F
East Afr Med J; 2000 Sep; 77(9):468-70. PubMed ID: 12862135
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study.
Khalil EA; Musa AM; Modabber F; El-Hassan AM
Ann Trop Paediatr; 2006 Dec; 26(4):357-61. PubMed ID: 17132302
[TBL] [Abstract][Full Text] [Related]
6. Dichotomy of protective cellular immune responses to human visceral leishmaniasis.
Khalil EA; Ayed NB; Musa AM; Ibrahim ME; Mukhtar MM; Zijlstra EE; Elhassan IM; Smith PG; Kieny PM; Ghalib HW; Zicker F; Modabber F; Elhassan AM
Clin Exp Immunol; 2005 May; 140(2):349-53. PubMed ID: 15807861
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
[TBL] [Abstract][Full Text] [Related]
8. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN
Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033
[TBL] [Abstract][Full Text] [Related]
9. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
[TBL] [Abstract][Full Text] [Related]
10. Interferon (IFN)-gamma , tumor necrosis factor-alpha , interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis.
Ansari NA; Ramesh V; Salotra P
J Infect Dis; 2006 Oct; 194(7):958-65. PubMed ID: 16960784
[TBL] [Abstract][Full Text] [Related]
11. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
Karki P; Koirala S; Parija SC; Sethi M; Das ML
Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
[TBL] [Abstract][Full Text] [Related]
12. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.
Khalil EA; El Hassan AM; Zijlstra EE; Mukhtar MM; Ghalib HW; Musa B; Ibrahim ME; Kamil AA; Elsheikh M; Babiker A; Modabber F
Lancet; 2000 Nov; 356(9241):1565-9. PubMed ID: 11075771
[TBL] [Abstract][Full Text] [Related]
13. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
14. Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers.
Kamil AA; Khalil EA; Musa AM; Modabber F; Mukhtar MM; Ibrahim ME; Zijlstra EE; Sacks D; Smith PG; Zicker F; El-Hassan AM
Trans R Soc Trop Med Hyg; 2003; 97(3):365-8. PubMed ID: 15228261
[TBL] [Abstract][Full Text] [Related]
15. Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study.
El-Sayed M; Anwar AE
J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):335-40. PubMed ID: 19744259
[TBL] [Abstract][Full Text] [Related]
16. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
[TBL] [Abstract][Full Text] [Related]
17. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis.
Ganguly S; Das NK; Panja M; Pal S; Modak D; Rahaman M; Mallik S; Guha SK; Pramanik N; Goswami R; Barbhuiya JN; Saha B; Chatterjee M
J Infect Dis; 2008 Jun; 197(12):1762-71. PubMed ID: 18444882
[TBL] [Abstract][Full Text] [Related]
18. Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar.
Ansari NA; Saluja S; Salotra P
Clin Immunol; 2006 Jun; 119(3):339-45. PubMed ID: 16540374
[TBL] [Abstract][Full Text] [Related]
19. Expression profiling of Sudanese visceral leishmaniasis patients pre- and post-treatment with sodium stibogluconate.
Salih MAM; Fakiola M; Lyons PA; Younis BM; Musa AM; Elhassan AM; Anderson D; Syn G; Ibrahim ME; Blackwell JM; Mohamed HS
Parasite Immunol; 2017 Jun; 39(6):. PubMed ID: 28370072
[TBL] [Abstract][Full Text] [Related]
20. Studies on the protective efficacy of second-generation vaccine along with standard antileishmanial drug in Leishmania donovani infected BALB/c mice.
Joshi J; Kaur S
Parasitology; 2014 Apr; 141(4):554-62. PubMed ID: 24618257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
